Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Gıancarlo Comı(Casa di Cura Columbus), Jeffrey A. Cohen(Dartmouth Health), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), James K. Sheffield, Neil Minton, Kartik Raghupathi, Ludwig Kappos(University Hospital of Basel), Hans‐Peter Hartung(The University of Sydney), Douglas L. Arnold(McGill University), Lawrence Steinman(Stanford University), Amit Bar‐Or(University of Pennsylvania), Eva Havrdová(Charles University), Bruce Cree(University of California, San Francisco), Ning Ding(University Hospital Bonn), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya)
Cited by 286
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k